The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 01, 2025

Filed:

Apr. 02, 2021
Applicants:

Dignity Health, Phoenix, AZ (US);

The Translational Genomics Research Institute, Phoenix, AZ (US);

Inventors:

Timothy G. Whitsett, Jr., Phoenix, AZ (US);

Landon J. Inge, Phoenix, AZ (US);

Assignees:

Dignity Health, San Francisco, CA (US);

The Translational Genomics Research Institute, Phoenix, AZ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 31/282 (2006.01); A61K 31/7068 (2006.01); A61K 33/24 (2019.01); A61K 33/243 (2019.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 31/282 (2013.01); A61K 31/7068 (2013.01); A61K 33/24 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 2300/00 (2013.01);
Abstract

Embodiments of the invention provide a method of treating cancer, the method comprising providing a subject having cancer cells, and contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor. Embodiments of the invention also provide a method of treating cancer in a subject, the method comprising the steps of: (a) receiving a sample of the cancer cells from the subject; (b) determining if at least a portion of the sample of the cancer cells is LKB1 deficient; and (c) contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor. Embodiments of the invention also provide a method of treating cancer in a subject, the method comprising contacting the cancer cells with a therapeutically effective amount of a Wee1 inhibitor and a therapeutically effective amount of a second pharmaceutical composition. Embodiments of the invention also provide a method of prognosing or determining the severity of cancer in a subject comprising (a) determining the presence or absence of LKB1 in the cancer cells of the subject; and (b) prognosing the severity of cancer based on the presence of LKB1 deficiency in the cancer cells of the subject.


Find Patent Forward Citations

Loading…